SG Americas Securities LLC Acquires New Shares in Turning Point Therapeutics (NASDAQ:TPTX)

SG Americas Securities LLC acquired a new stake in Turning Point Therapeutics (NASDAQ:TPTX) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 38,935 shares of the company’s stock, valued at approximately $1,464,000. SG Americas Securities LLC owned approximately 0.12% of Turning Point Therapeutics as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in TPTX. Tower Research Capital LLC TRC acquired a new stake in shares of Turning Point Therapeutics during the second quarter valued at about $25,000. JPMorgan Chase & Co. acquired a new stake in shares of Turning Point Therapeutics during the second quarter valued at about $71,000. Wells Fargo & Company MN acquired a new stake in shares of Turning Point Therapeutics during the second quarter valued at about $72,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Turning Point Therapeutics during the second quarter valued at about $90,000. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Turning Point Therapeutics during the third quarter valued at about $118,000. 51.31% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have recently commented on TPTX. Roth Capital began coverage on Turning Point Therapeutics in a research note on Thursday. They set a “buy” rating and a $65.00 price target on the stock. Guggenheim began coverage on Turning Point Therapeutics in a research note on Wednesday, July 24th. They set a “buy” rating and a $58.00 price target on the stock. Wells Fargo & Co lifted their price target on Turning Point Therapeutics from $53.00 to $62.00 and gave the company an “outperform” rating in a research note on Wednesday, September 4th. Zacks Investment Research raised Turning Point Therapeutics from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a research note on Friday, November 8th. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Turning Point Therapeutics in a research note on Tuesday, November 12th. Eleven equities research analysts have rated the stock with a buy rating, Turning Point Therapeutics presently has a consensus rating of “Buy” and an average target price of $55.00.

Turning Point Therapeutics stock opened at $50.88 on Monday. The stock’s 50 day moving average is $39.25 and its 200 day moving average is $40.40. The company has a quick ratio of 36.64, a current ratio of 36.64 and a debt-to-equity ratio of 0.01. Turning Point Therapeutics has a one year low of $24.21 and a one year high of $58.56.

Turning Point Therapeutics (NASDAQ:TPTX) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.04). On average, equities research analysts forecast that Turning Point Therapeutics will post -3.08 EPS for the current fiscal year.

In related news, Director Simeon George acquired 177,777 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were bought at an average cost of $45.00 per share, with a total value of $7,999,965.00. Also, CFO Yi Larson acquired 2,222 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was bought at an average cost of $45.00 per share, for a total transaction of $99,990.00. Over the last ninety days, insiders purchased 189,999 shares of company stock worth $8,549,955.

About Turning Point Therapeutics

Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

Recommended Story: What is the formula for the cash asset ratio?

Institutional Ownership by Quarter for Turning Point Therapeutics (NASDAQ:TPTX)

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.